Key takeaways
Janumet (sitagliptin/metformin) and repaglinide are both medications used to manage Type 2 diabetes, but they have some key differences. Janumet combines two medications: sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide). It helps control blood sugar by improving insulin function and reducing glucose production and absorption. Janumet is taken either twice daily with meals (immediate-release) or once daily (extended-release). Repaglinide, on the other hand, is a meglitinide that stimulates the pancreas to produce more insulin and is taken before each meal. Unlike Janumet, repaglinide is available in a generic form. However, repaglinide can cause weight gain and has a higher risk of causing low blood sugar compared to Janumet. While Janumet is not recommended for those with severe kidney problems, repaglinide should not be used with NPH-insulin due to the risk of heart damage.
